Advances in the treatment of brain metastases in non-small cell lung cancer with rare driver-gene alterations
- 1Department of Medical Oncology,Jiangsu Cancer Hospital,Jiangsu Institute of Cancer Research,The Affiliated CancerHospital of Nanjing Medical University,Nanjing,Jiangsu 210009,China
Abstract
With advances in molecular profiling and targeted therapies for non-small cell lung cancer(NSCLC),central nervous system(CNS)involvement and its management in patients with rare driver-gene alterations have received increasing attention. The development of next-generation small-molecule inhibitors and antibody-drug conjugates(ADCs)has improved intracranial disease control in some patients; however,the level of evidence for intracranial treatment varies substantially across different driver alterations,and data on CNS-specific endpoints remain limited. The rational integration of targeted therapies with local treatments,such as stereotactic radiosurgery(SRS),together with multidisciplinary team(MDT)integrated management,has become an important therapeutic strategy. This review summarizes the clinical and molecular characteristics of brain metastases in NSCLC harboring rare driver-gene alterations,with a focus on advances in systemic therapies and multidisciplinary treatment strategies.
Related
- Efficacy and safety of narlumosbart in combination with stereotactic body radiation therapy followed by first-line chemotherapy combined with immunotherapy in advanced driver gene-negative non-small cell lung cancer patients with bone metastases: a phase II, single-arm, single-centre clinical trial protocol
- The molecular heterogeneity and clinical impact of genomic driver alterations in prostate cancer
- The Enemy of My Enemy: Two Cases of De Novo Metastatic Small-Cell Neuroendocrine Prostate Cancer with BRCA2 Alterations and Brain Metastases.
- Clinically actionable genomic alterations in breast cancer brain metastases
- Central nervous system efficacy of third generation vs. first generation EGFR-TKIs in the first line treatment for EGFR-mutated non-small cell lung cancer with central nervous system metastases: a systematic review and meta-analysis of phase 3 randomized controlled trials
BibTeX
@article{xi2026advances,
title = {{Advances in the treatment of brain metastases in non-small cell lung cancer with rare driver-gene alterations}},
author = {CHEN Xi and LIU Ying and LI Feiyang and HU Shuyi and WU Sirui and FANG Ying and SHA Huanhuan and ZHOU Guoren},
journal = {Zhongguo linchuang yanjiu},
year = {2026},
month = oct,
doi = {10.13429/j.cnki.cjcr.2026.10.002},
url = {https://doi.org/10.13429/j.cnki.cjcr.2026.10.002},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Advances in the treatment of brain metastases in non-small cell lung cancer with rare driver-gene alterations
AU - CHEN Xi
AU - LIU Ying
AU - LI Feiyang
AU - HU Shuyi
AU - WU Sirui
AU - FANG Ying
AU - SHA Huanhuan
AU - ZHOU Guoren
PY - 2026
DA - 2026/10/26
JO - Zhongguo linchuang yanjiu
DO - 10.13429/j.cnki.cjcr.2026.10.002
UR - https://doi.org/10.13429/j.cnki.cjcr.2026.10.002
AB - With advances in molecular profiling and targeted therapies for non-small cell lung cancer(NSCLC),central nervous system(CNS)involvement and its management in patients with rare driver-gene alterations have received increasing attention. The development of next-generation small-molecule inhibitors and antibody-drug conjugates(ADCs)has improved intracranial disease control in some patients; however,the level of evidence for intracranial treatment varies substantially across different driver alterations,and data on CNS-specific endpoints remain limited. The rational integration of targeted therapies with local treatments,such as stereotactic radiosurgery(SRS),together with multidisciplinary team(MDT)integrated management,has become an important therapeutic strategy. This review summarizes the clinical and molecular characteristics of brain metastases in NSCLC harboring rare driver-gene alterations,with a focus on advances in systemic therapies and multidisciplinary treatment strategies.
SN - 1674-8182
ER -